Mariner, LLC Neu Base Therapeutics, Inc. Transaction History

Mariner, LLC

  • $55.8 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$0.41 - $1.3 $6,355 - $20,150
15,500 New
15,500 $6,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email